Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025

The 2025 American Society of Clinical Oncology Annual Meeting will take place from May 30 to June 3, 2025 in Chicago, Illinois. This year’s conference features several sessions spanning genitourinary malignancies.

In a recent interview with Urology Times®, Andrew J. Armstrong, MD, MSc, shared key abstracts that he’s most looking forward to seeing in the prostate cancer space. Armstrong, who is a professor of medicine at Duke University, will be presenting long-term follow-up data from the phase 3 ARCHES trial (NCT02677896) at this year’s meeting.¹ Overall, ARCHES assessed the efficacy of adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) vs ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Armstrong began by highlighting the phase 3 AMPLITUDE study (NCT04497844).

“We'll also see data from what's called the AMPLITUDE study, which is testing the benefits of a PARP inhibitor, in this case, niraparib, when added as treatment intensification to abiraterone,” he explained. “It'll be the first phase 3 PARP inhibitor trial to read out.”

Armstrong also touched on data coming down the pike, which are poised to further enhance precision medicine in the hormone-sensitive space.

He said, “Over time, we're also developing hormone-sensitive trials where we're building on ARCHES-like regimens to test PSMA lutetium; that's the PSMAddition study. [We’re also] testing EZH2 inhibitors, testing AKT inhibitors like the CAPItello study. There's a lot of agent development and precision medicine development in this space to really build on the results that we've established from ARCHES.”

REFERENCE

1. Armstrong A, Petrylak D, Shore N, et al. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol. 2025. doi: 10.1200/JCO.2025.43.16_suppl.5005. Abstract 5005